Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Habek

Showing results (221-230 of 251) with videos related to

Pageof 26
Sort By:
Neurology and Therapy|March 14, 2022
COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with OfatumumabAnne H Cross, Silvia Delgado, Mario Habek, et al.
Multiple Sclerosis and Related Disorders|September 9, 2023
Impact of the autonomic dysfunction on the quality of life in people with NMOSD and MS: An international cross-sectional studyMarko Andabaka, Tatjana Pekmezovic, Luka Crnosija, et al.
Journal of Neuroimmunology|August 3, 2023
Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centersIvan Adamec, Gregor Brecl Jakob, Cecilia Rajda, et al.
European Journal of Neurology|May 22, 2022
Sudomotor dysfunction in people with neuromyelitis optica spectrum disordersMario Habek, Marko Andabaka, Alessandra Fanciulli, et al.
International Journal of Molecular Sciences|September 13, 2025
Real-World Laboratory Analysis of Molecular Biomarkers in Multiple Sclerosis Centers in Central-Eastern European Countries Covering 107 Million InhabitantsAnett Járdánházy, Thomas Berger, Harald Hegen, et al.
The Lancet. Neurology|July 19, 2025
Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension studyAmit Bar-Or, Michal Dufek, Hrvoje Budincevic, et al.
International Journal of Environmental Research and Public Health|February 7, 2020
Content and Delivery of Physical Therapy in Multiple Sclerosis across Europe: A SurveyKamila Řasová, Jenny Freeman, Davide Cattaneo, et al.
Multiple Sclerosis and Related Disorders|March 27, 2018
Physiotherapeutic interventions in multiple sclerosis across Europe: Regions and other factors that matterPatrícia Martinková, Jenny Freeman, Adéla Drabinová, et al.
Multiple Sclerosis and Related Disorders|January 24, 2026
Real-world effectiveness and safety of ofatumumab in relapsing multiple sclerosis: A multicenter cohort studyKatarina Tešija, Magdalena Krbot Skorić, Vanja Bašić Kes, et al.
Frontiers in Neurology|April 11, 2019
Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical SettingsKrista Barclay, Robert Carruthers, Anthony Traboulsee, et al.
Pageof 26

Showing results (221-230 of 251) with videos related to

Sort By:
Pageof 26
Neurology and Therapy|March 14, 2022
COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with OfatumumabAnne H Cross, Silvia Delgado, Mario Habek, et al.
Multiple Sclerosis and Related Disorders|September 9, 2023
Impact of the autonomic dysfunction on the quality of life in people with NMOSD and MS: An international cross-sectional studyMarko Andabaka, Tatjana Pekmezovic, Luka Crnosija, et al.
Journal of Neuroimmunology|August 3, 2023
Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centersIvan Adamec, Gregor Brecl Jakob, Cecilia Rajda, et al.
European Journal of Neurology|May 22, 2022
Sudomotor dysfunction in people with neuromyelitis optica spectrum disordersMario Habek, Marko Andabaka, Alessandra Fanciulli, et al.
International Journal of Molecular Sciences|September 13, 2025
Real-World Laboratory Analysis of Molecular Biomarkers in Multiple Sclerosis Centers in Central-Eastern European Countries Covering 107 Million InhabitantsAnett Járdánházy, Thomas Berger, Harald Hegen, et al.
The Lancet. Neurology|July 19, 2025
Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension studyAmit Bar-Or, Michal Dufek, Hrvoje Budincevic, et al.
International Journal of Environmental Research and Public Health|February 7, 2020
Content and Delivery of Physical Therapy in Multiple Sclerosis across Europe: A SurveyKamila Řasová, Jenny Freeman, Davide Cattaneo, et al.
Multiple Sclerosis and Related Disorders|March 27, 2018
Physiotherapeutic interventions in multiple sclerosis across Europe: Regions and other factors that matterPatrícia Martinková, Jenny Freeman, Adéla Drabinová, et al.
Multiple Sclerosis and Related Disorders|January 24, 2026
Real-world effectiveness and safety of ofatumumab in relapsing multiple sclerosis: A multicenter cohort studyKatarina Tešija, Magdalena Krbot Skorić, Vanja Bašić Kes, et al.
Frontiers in Neurology|April 11, 2019
Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical SettingsKrista Barclay, Robert Carruthers, Anthony Traboulsee, et al.
Pageof 26